Tg Immunopharma Receives Fda Approval To Initiate Clinical Trial For Tgi-6 Bispecific Antibody

Tg Immunopharma Receives Fda Approval To Initiate Clinical Trial For Tgi-6 Bispecific Antibody

By, Admin 21 June 2023

Tg Immunopharma Has Announced That The Fda Has Approved The Clinical Investigation Of Tgi-6, For The Development Of Breakthrough Bispecific Antibody.Tgi-6 Is A Novel Antibody Developed To Target Both Tumour-Associated Antigens (Taa) And Cd3 Molecules. This Dual Targeting Mechanism Is Designed To Enhance Anti-Tumour Responses. By Binding To Taas, Which Are Specific To Cancer Cells, Tgi-6 Can Directly Recognise And Attack Tumour Cells.Tgi-6, A Novel Therapeutic Agent, Has Been Specifically Engineered To Uphold Potent Cytotoxic Effects While Mitigating The Potential For Cytokine Release Syndrome (Crs). Tgi-6 Has Demonstrated Superior Antitumor Activity And Safety In Preclinical Studies.Tgi-6 Taa Is Highly Expressed In Several Solid Tumours, Including Colon Cancer, Breast Cancer, Hepatocellular Carcinoma, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer And Many Others. This Makes Tgi-6 A Promising Candidate For The Treatment Of Many Solid Tumours.Preclinical Investigations Have Showcased The Remarkable Potential Of Tgi-6, As It Achieved Complete Regression Of Tumours In Animal Models Of Colourectal Cancer Following A Single Administration. Tgi-6 Is Specifically Designed To Uphold Potent Cytotoxic Activity While Mitigating The Potential For Cytokine Release Syndrome (Crs).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!